{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T14:30:24Z","timestamp":1771684224611,"version":"3.50.1"},"reference-count":51,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T00:00:00Z","timestamp":1540166400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Malignant pleural mesothelioma (MPM) is a rare disease of the pleura and is largely related to asbestos exposure. Despite recent advancements in technologies and a greater understanding of the disease, the prognosis of MPM remains poor; the median overall survival rate is about 6 to 9 months in untreated patients. The main therapeutic strategies for MPM are surgery, chemotherapy, and radiation therapy (RT). The two main surgical approaches for MPM are extrapleural pneumonectomy (EPP), in which the lung is removed en bloc, and pleurectomy\/decortication, in which the lung stays <ns4:italic>in situ<\/ns4:italic>. Chemotherapy usually consists of a platinum-based chemotherapy, such as cisplatin, often combined with a folate antimetabolite, such as pemetrexed. More recently, immunotherapy has emerged as a possible therapeutic strategy for MPM. Evidence suggests that single-modality treatments are not an effective therapeutic approach for MPM. Therefore, researchers have started to explore different multimodality treatment approaches, in which often combinations of surgery, chemotherapy, immunotherapy, and RT are investigated. There is still no definitive answer to the question of which multimodality treatment combinations are most effective in improving the poor prognosis of MPM. Research into the effects of trimodality treatment approaches have found that radical approaches such as EPP and hemithoracic RT post-EPP are less effective than was previously assumed. In general, there are still a great number of unanswered questions and unknown factors regarding the ideal treatment approach for MPM. Hopefully, more research into multimodality therapy will provide insight into which combination of treatment modalities is most effective.<\/ns4:p>","DOI":"10.12688\/f1000research.15796.1","type":"journal-article","created":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T06:20:09Z","timestamp":1540189209000},"page":"1681","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":35,"title":["Multimodality treatment of malignant pleural mesothelioma"],"prefix":"10.12688","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0169-0694","authenticated-orcid":false,"given":"Lawek","family":"Berzenji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1962-8821","authenticated-orcid":false,"given":"Paul","family":"Van Schil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2560","published-online":{"date-parts":[[2018,10,22]]},"reference":[{"key":"ref-1","first-page":"32","article-title":"Peritoneal mesothelioma: a review.","volume":"9","author":"A Bridda","year":"2007","journal-title":"MedGenMed."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"1591-603","DOI":"10.1056\/NEJMra050152","article-title":"Advances in malignant mesothelioma.","volume":"353","author":"B Robinson","year":"2005","journal-title":"N Engl J Med."},{"key":"ref-3","doi-asserted-by":"crossref","first-page":"345-55","DOI":"10.1016\/j.soc.2012.12.004","article-title":"Multimodality treatment of pleural mesothelioma.","volume":"22","author":"D Shersher","year":"2013","journal-title":"Surg Oncol Clin N Am."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"102-10","DOI":"10.1055\/s-0031-1272874","article-title":"Update on malignant pleural mesothelioma.","volume":"32","author":"N Campbell","year":"2011","journal-title":"Semin Respir Crit Care Med."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"1189-203","DOI":"10.1016\/j.jtho.2018.04.023","article-title":"New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.","volume":"13","author":"F Galateau Salle","year":"2018","journal-title":"J Thorac Oncol."},{"key":"ref-6","first-page":"70-9","article-title":"Mesothelioma: a review.","volume":"12","author":"F Mott","year":"2012","journal-title":"Ochsner J."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"491-6","DOI":"10.3978\/j.issn.2225-319X.2012.11.04","article-title":"Malignant pleural mesothelioma: an epidemiological perspective.","volume":"1","author":"B Robinson","year":"2012","journal-title":"Ann Cardiothorac Surg."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"v31-9","DOI":"10.1093\/annonc\/mdv199","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"26 Suppl 5","author":"P Baas","year":"2015","journal-title":"Ann Oncol."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"271-4","DOI":"10.5694\/mja11.10125","article-title":"Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation.","volume":"195","author":"N Olsen","year":"2011","journal-title":"Med J Aust."},{"key":"ref-10","first-page":"257-62","article-title":"The global spread of asbestos.","volume":"80","author":"A Frank","year":"2014","journal-title":"Ann Glob Health."},{"key":"ref-11","first-page":"393-411","article-title":"Occupational and environmental exposures and cancers in developing countries.","volume":"80","author":"D Hashim","year":"2014","journal-title":"Ann Glob Health."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"851-8","DOI":"10.1136\/oemed-2017-104298","article-title":"Estimation of the global burden of mesothelioma deaths from incomplete national mortality data.","volume":"74","author":"C Odgerel","year":"2017","journal-title":"Occup Environ Med."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"CD003880","DOI":"10.1002\/14651858.CD003880.pub4","article-title":"Radiotherapy for malignant pleural mesothelioma.","author":"E Chapman","year":"2006","journal-title":"Cochrane Database Syst Rev."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"475-88","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy.","volume":"17","author":"T Yap","year":"2017","journal-title":"Nat Rev Cancer."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"2112-9","DOI":"10.1016\/j.jtho.2016.09.124","article-title":"The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma.","volume":"11","author":"V Rusch","year":"2016","journal-title":"J Thorac Oncol."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"2100-11","DOI":"10.1016\/j.jtho.2016.09.121","article-title":"The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma.","volume":"11","author":"D Rice","year":"2016","journal-title":"J Thorac Oncol."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"2089-99","DOI":"10.1016\/j.jtho.2016.08.147","article-title":"The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma.","volume":"11","author":"A Nowak","year":"2016","journal-title":"J Thorac Oncol."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"543-549","DOI":"10.21037\/tlcr.2018.07.05","article-title":"The eighth TNM classification for malignant pleural mesothelioma.","volume":"7","author":"L Berzenji","year":"2018","journal-title":"Transl Lung Cancer Res."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"CD012605","DOI":"10.1002\/14651858.CD012605.pub2","article-title":"Radical multimodality therapy for malignant pleural mesothelioma.","volume":"1","author":"O Abdel-Rahman","year":"2018","journal-title":"Cochrane Database Syst Rev."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"232","DOI":"10.21037\/atm.2017.03.82","article-title":"Extrapleural pneumonectomy (EPP) vs. pleurectomy decortication (P\/D).","volume":"5","author":"H Batirel","year":"2017","journal-title":"Ann Transl Med."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"550-555","DOI":"10.21037\/tlcr.2018.07.07","article-title":"Extrapleural pneumonectomy: still indicated?","volume":"7","author":"A Domen","year":"2018","journal-title":"Transl Lung Cancer Res."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"240-5","DOI":"10.1016\/j.lungcan.2013.11.026","article-title":"A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.","volume":"83","author":"C Cao","year":"2014","journal-title":"Lung Cancer."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"151-5","DOI":"10.1016\/j.lungcan.2011.12.009","article-title":"Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: a harmful procedure.","volume":"77","author":"O Rena","year":"2012","journal-title":"Lung Cancer."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"1077-82","DOI":"10.1093\/ejcts\/ezw215","article-title":"Comorbidity, postoperative morbidity and survival in patients undergoing radical surgery for malignant pleural mesothelioma.","volume":"50","author":"M Infante","year":"2016","journal-title":"Eur J Cardiothorac Surg."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"51-6","DOI":"10.1038\/sj.bjc.6604442","article-title":"Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.","volume":"99","author":"G Ceresoli","year":"2008","journal-title":"Br J Cancer."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"32-6","DOI":"10.1016\/S0093-7754(03)00283-5","article-title":"Pemetrexed (Alimta, MTA, multitargeted antifolate, LY231514) for malignant pleural mesothelioma.","volume":"30","author":"C Manegold","year":"2003","journal-title":"Semin Oncol."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"502-7","DOI":"10.3978\/j.issn.2225-319X.2012.11.12","article-title":"Multimodality therapy for malignant pleural mesothelioma.","volume":"1","author":"W Weder","year":"2012","journal-title":"Ann Cardiothorac Surg."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"1362-9","DOI":"10.1183\/09031936.00039510","article-title":"Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial.","volume":"36","author":"P Van Schil","year":"2010","journal-title":"Eur Respir J."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"960-6","DOI":"10.1093\/ejcts\/ezx427","article-title":"Predictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma.","volume":"53","author":"D Nelson","year":"2018","journal-title":"Eur J Cardiothorac Surg."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"3591-600","DOI":"10.1200\/JCO.2017.72.9012","article-title":"Nintedanib Plus Pemetrexed\/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.","volume":"35","author":"F Grosso","year":"2017","journal-title":"J Clin Oncol."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"LBA8507","DOI":"10.1200\/JCO.2017.35.18_suppl.LBA8507","article-title":"Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial.","volume":"35","author":"A Scherpereel","year":"2017","journal-title":"JCO."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"276-84","DOI":"10.1007\/s00066-016-1092-7","article-title":"Role of postoperative radiotherapy in the management of malignant pleural mesothelioma: A propensity score matching of the SEER database.","volume":"193","author":"O Abdel-Rahman","year":"2017","journal-title":"Strahlenther Onkol."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"1343-73","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.","volume":"36","author":"H Kindler","year":"2018","journal-title":"J Clin Oncol."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"1269-83","DOI":"10.1016\/j.jtho.2018.06.011","article-title":"Scientific Advances and New Frontiers in Mesothelioma Therapeutics.","volume":"13","author":"L Mutti","year":"2018","journal-title":"J Thorac Oncol."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"139-44","DOI":"10.1120\/jacmp.v17i2.5980","article-title":"A pilot study of volumetric-modulated arc therapy for malignant pleural mesothelioma.","volume":"17","author":"L Runxiao","year":"2016","journal-title":"J Appl Clin Med Phys."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"69-73","DOI":"10.1111\/ajco.12788","article-title":"PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma.","volume":"14","author":"B Nguyen","year":"2018","journal-title":"Asia Pac J Clin Oncol."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"273-80","DOI":"10.2217\/imt-2016-0123","article-title":"Anti-CTLA-4 therapy for malignant mesothelioma.","volume":"9","author":"A Guazzelli","year":"2017","journal-title":"Immunotherapy."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"1104-11","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: An open-label, single-arm, phase 2 trial.","volume":"14","author":"L Calabr\u00f2","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"301-9","DOI":"10.1016\/S2213-2600(15)00092-2","article-title":"Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: An open-label, single-arm, phase 2 study.","volume":"3","author":"L Calabr\u00f2","year":"2015","journal-title":"Lancet Respir Med."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"623-30","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.","volume":"18","author":"E Alley","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"451-60","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.","volume":"6","author":"L Calabr\u00f2","year":"2018","journal-title":"Lancet Respir Med."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"TPS8581","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS8581","article-title":"Checkmate 743: A phase 3, randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma.","volume":"35","author":"G Zalcman","year":"2017","journal-title":"JCO."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"89-95","DOI":"10.1016\/j.lungcan.2007.02.004","article-title":"Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results.","volume":"57","author":"F Rea","year":"2007","journal-title":"Lung Cancer."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"186-8","DOI":"10.1093\/jjco\/hyn145","article-title":"A feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation for malignant pleural mesothelioma.","volume":"39","author":"T Yamanaka","year":"2009","journal-title":"Jpn J Clin Oncol."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"763-72","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study.","volume":"12","author":"T Treasure","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"1651-8","DOI":"10.1016\/S1470-2045(15)00208-9","article-title":"Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17\/04): a randomised, international, multicentre phase 2 trial.","volume":"16","author":"R Stahel","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"797-831","DOI":"10.1016\/S0039-6109(02)00033-6","article-title":"Malignant mesothelioma: options for management.","volume":"82","author":"S Singhal","year":"2002","journal-title":"Surg Clin North Am."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"194-7","DOI":"10.1136\/thoraxjnl-2013-203846","article-title":"Surgery in the treatment of malignant pleural mesothelioma: recruitment into trials should be the default position.","volume":"69","author":"A Datta","year":"2014","journal-title":"Thorax."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"3354-62","DOI":"10.1200\/JCO.2017.73.8401","article-title":"Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis.","volume":"35","author":"D Nelson","year":"2017","journal-title":"J Clin Oncol."},{"key":"ref-50","doi-asserted-by":"publisher","first-page":"1386-96","DOI":"10.1016\/S1470-2045(17)30621-6","article-title":"Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.","volume":"18","author":"N van Zandwijk","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"1012-21","DOI":"10.1016\/j.jtho.2018.04.034","article-title":"Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1).","volume":"13","author":"S Armato","year":"2018","journal-title":"J Thorac Oncol."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/7-1681\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/7-1681\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/7-1681\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T12:17:23Z","timestamp":1553861843000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/7-1681\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,22]]},"references-count":51,"URL":"https:\/\/doi.org\/10.12688\/f1000research.15796.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.17243.r39662","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.17243.r39661","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,22]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/7-1681\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.17243.r39661, Michele Maio, Luana Calabro, Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Medical Oncology and Immunotherapy, Siena, Italy, 22 Oct 2018, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/7-1681\/v1#referee-response-39661","order":0,"name":"referee-response-39661","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.17243.r39662, Sonja Klebe, SA Pathology at Flinders Medical Centre, Department of Surgical Pathology, Adelaide 5001, Australia, 22 Oct 2018, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/7-1681\/v1#referee-response-39662","order":1,"name":"referee-response-39662","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}